My question is always how much are the real effective costs monthly/annually? The numbers always seem wild and are frequently quoted in thousands annually, so when you read things like: > “The amount of profit that they might be giving up [by capping costs] is relatively limited,”...

I am honest, I don't know what to believe, and I don't directly know anyone who uses insulin to even have any anecdota.

Tangent and I don't know how productive it is to discuss, does this have anything with the GLP-1s (Ozempic/Mounjaro et al.)?

The pressure is coming from legislation, and while there is no doubt lobbying going on, am I wrong that it doesn't feel like the same relentless pushback from the triumvirate? Is it just that there is critical mass to drive change, or is the bitter fight not worth it when they have potential weight management products applicable to a much wider audience?